Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspective

Kidney International

Volumn 70, Issue 1, 2006, Pages 26-33

  Zoccali, C ^a,b  

^a CNR   (Italy)

^b Ospedali Riuniti (VI Piano)   (Italy)

Author keywords

Cardiovascular risk; CKD; Emerging risk factors; ESRD; Raditional risk factors; Uremia

Indexed keywords

C REACTIVE PROTEIN;

ATHEROGENESIS; CARDIOVASCULAR RISK; CORONARY RISK; EPIDEMIOLOGICAL DATA; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; KIDNEY DISEASE; KIDNEY FAILURE; MORTALITY; POPULATION RISK; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; RENAL INSUFFICIENCY; RISK FACTORS;

EID: 33745711918     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000417     Document Type: Review

References (86)

1. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framinham Study. Am J Cardiol 1976; 38: 46-51.
2. Coresh J, Byrd-Holt D, Astor BC et al. Chronic kidney disease awareness, prevalence, and trends among US adults, 1999-2000. J Am Soc Nephrol 2005; 16: 180-188.
3. Hsu CY, Vittinghoff E, Lin F, Shlipak MG. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004; 141: 95-101.
4. Culleton BF, Larson MG, Evans JC et al. Prevalence and correlates of elevated serum creatinine levels: the Framingham Heart Study. Arch Intern Med 1999; 159: 1785-1790.
5. Fox CS, Larson MG, Leip EP et al. Predictors of new-onset kidney disease in a community based population. JAMA 2004; 291: 844-850.
6. Chadban SJ, Briganti EM, Kerr PG et al. Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol 2003; 14(Suppl 2): S131-8.
7. Pinto-Sietsma SJ, Mulder J, Janssen WM et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133: 585-591.
8. Verhave JC, Gansevoort RT, Hillege HL et al. PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 2004; 92: S18-S21.
9. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134-2140.
10. McClellan WM, Ramirez SBP, Jurkovitz C. Screening for chronic kidney disease: unresolved issues. J Am Soc Nephrol 2003; 14(Suppl 2): S81-S87.
11. Perneger TV, Klag MJ, Feldman HI, Whelton PK. Projections of hypertension-related renal disease in middle-aged residents of the United Status. JAMA 1993; 269: 1272-1277.
12. Segura J, Campo C, Gil P et al. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616-1622.
13. McClellan WM, Langston RD, Presley R. Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004; 15: 1912-1919.
14. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004; 109: 1004-1009.
15. Shlipak MG, Smith GL, Rathore SS et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol 2004; 15: 2195-2203.
16. Culleton BF, Larson MG, Wilson PW et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214-2219.
17. Manjunath G, Tighiouart H, Ibrahim H et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55.
18. Garg AX, Clark WF, Haynes RB, House AA. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I. Kidney Int 2002; 61: 1486-1494.
19. Muntner P, He J, Hamm L et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745-753.
20. Weiner DE, Tighiouart H, Amin MG et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15: 1307-1315.
21. Schillaci G, Reboldi G, Verdecchia P. High-normal serum creatinine concentration is a predictor of cardiovascular risk in essential hypertension. Arch Intern Med 2001; 161: 886-891.
22. De Leeuw PW, Thijs L, Birkenhager WH et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213-2222.
23. Anavekar NS, McMurray JJ, Velazquez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295.
24. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 23: 1296-1305.
25. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9: S16-S23.
26. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the 'only-50%' myth. Arch Intern Med 2001; 161: 2657-2660.
27. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
28. Sarnak MJ, Coronado BE, Greene T et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327-335.
29. Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int 2003; 63(Suppl 85): S105-S110.
30. Locatelli F, Canaud B, Eckardt KU et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280.
31. Zoccali C, Mallamaci F, Tripepi G et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.
32. Johnson R, Herrera-Acosta J, Schreiner GF, Rodriguez Iturbe B. Mechanisms of disease: subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002; 346: 913-923.
33. Diamond JR. Analogous pathobiologic mechanisms in glomerulosclerosis and atherosclerosis. Kidney Int 1991; 31(Suppl): S29-S34.
34. Brocco E, Fioretto P, Mauer M et al. Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int 1997; 63(Suppl): S40-S44.
35. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134.
36. Gouva C, Nikolopoulos P, Iannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
37. Iaina A, Silverberg DS, Wexler D. Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome. Nat Clin Pract Cardiovasc Med 2005; 2: 95-100.
38. Volkova N, Arab L. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. Am J Kidney Dis 2006; 47: 24-36.
39. De Boer IH, Gorodetskaya I, Young B et al. The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease. J Am Soc Nephrol 2002; 13: 2762-2769.
40. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252.
41. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 68: 429-436.
42. Ritz E. The clinical management of hyperphosphatemia. J Nephrol 2005; 218: 221-228.
43. Hoogeveen EK, Kostense PJ, Jager A et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998; 54: 203-209.
44. Ninomiya T, Kiyohara Y, Kubo M et al. Hyperhomocysteinemia and the development of chronic kidney disease in a general population: the Hisayama study. Am J Kidney Dis 2004; 44: 437-445.
45. Chauveau P, Chadefaux B, Coude M et al. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1997; 41(Suppl): S72-S77.
46. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325: 1202.
47. Zoccali C, Enia G, Tripepi G et al. Clinical epidemiology of non-traditional risk factors in peritoneal dialysis patients. Peritoneal Dial Int 2005; 25(Suppl 3): S84-S87.
48. Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61: 609-614.
49. Sezer S, Ozdemir FN, Arat Z et al. The association of interdialytic weight gain with nutritional parameters and mortality risk in hemodialysis patients. Ren Fail 2002; 24: 37-48.
50. Stuveling EM, Hillege HL, Bakker SJ et al. C-reactive protein is associated with renal function abnormalities in a non-diabetic population. Kidney Int 2003; 63: 654-661.
51. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397.
52. Tonelli M, Isles C, Craven T et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005; 112: 171-178.
53. Tonelli M, Isles C, Curhan GC et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2005; 110: 1557-1563.
54. Landray MJ, Wheeler DC, Lip GY et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244-253.
55. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658.
56. Zoccali C, Benedetto FA, Mallamaci F et al. Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed investigators. Cardiovascular risk extended evaluation in dialysis patients. J Hypertens 2000; 18: 1207-1213.
57. Stenvinkel P, Wanner C, Metzger T et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798.
58. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476.
59. Wanner C, Krane V, Marz W et al. German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
60. Tintut Y, Patel J, Territo M et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 2002; 105: 650-655.
61. Wang AY, Wang M, Woo J et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14: 159-168.
62. Kaysen GA, Don BR. Factors that affect albumin concentration in dialysis patients and their relationship to vascular disease. Kidney Int 2003; 63(Suppl 84): S94-S97.
63. Zoccali C, Benedetto F, Mallamaci F et al. Fibrinogen, inflammation and concentric left ventricular hypertrophy in chronic renal failure. Eur J Clin Invest 2003; 33: 561-566.
64. Zoccali C, Mallamaci F, Tripepi G et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003; 254: 132-139.
65. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328.
66. Zoccali C, Mallamaci F, Parlongo S et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354-1359.
67. Narkiewicz K, Somers VK. Sympathetic nerve activity in obstructive sleep apnoea. Acta Physiol Scand 2003; 177: 385-390.
68. Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 2002; 13: 729-733.
69. Zoccali C, Mallamaci F, Tripepi G et al. Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 2002; 40: 41-46.
70. Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 2004; 17: 821-825.
71. Kielstein JT, Boger RH, Bode-Boger SM et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002; 13: 170-176.
72. Kielstein JT, Impraim B, Simmel S et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-177.
73. Fujiwara N, Osanai T, Kamada T et al. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000; 101: 856-861.
74. Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant 2001; 16(Suppl 1): 60-62.
75. Ravani P, Tripepi G, Malberti F et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449-2455.
76. Fliser D, Kronenberg F, Kielstein JT et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005; 16: 2456-2461.
77. Valkonen VP, Paiva H, Salonen JT et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128.
78. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
79. Travagli RA, Gillis RA. Nitric oxide-mediated excitatory effect on neurons of dorsal motor nucleus of vagus. Am J Physiol 1994; 266: G154-G160.
80. Hijmering ML, Stroes ES, Olijhoek J et al. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 2002; 39: 683-688.
81. Mallamaci F, Tripepi G, Maas R et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol 2004; 15: 435-441.
82. Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174.
83. De Nicola N, Minutolo R, Chiodini P et al. Global approach to cardiovascular risk in chronic kidney disease. Kidney Int 2006; 69: 538-545.
84. Eckardt KU. Cardiovascular risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) Trial. The CREATE trial - building the evidence. Nephrol Dial Transplant 2001; 16(Suppl 2): 16-18.
85. Baigent C, Landray M, Leaper C. First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis 2005; 45: 473-484.
86. Lenfant C. Shattuck lecture. Clinical research to clinical practice: lost in translation? N Engl J Med 2003; 49: 868-874.